Fangzhou Recognized at Key Industry Forum
SHANGHAI — Fangzhou Inc. (06086.HK), a prominent player in AI-driven Internet healthcare solutions, was honored with the title of “Outstanding Growth Story in Hong Kong Stocks” during the recent China Capital Market Development Forum in Shanghai. This event aimed to showcase innovative companies within Hong Kong's dynamic stock market.
Recognition for Exceptional Growth
This accolade emphasizes companies that demonstrate exceptional performance in technological advancement and earnings growth. The award not only spotlights Fangzhou's impressive operational results but also expresses a strong belief in the company’s ongoing commitment to innovation in healthcare.
CEO's Vision and Company Performance
Dr. Xie Fangmin, the founder, chairman, and CEO of Fangzhou, shared his thoughts on this achievement: “This award truly validates our dedication to driving innovation and growth. More importantly, it underscores the significant value that AI can contribute to managing chronic diseases.”
Impressive Interim Results
In its latest interim report, Fangzhou revealed impressive financial figures, with revenues soaring to RMB 1.5 billion, marking a 12.9% increase compared to the previous year. The company achieved a net profit of RMB 12.5 million, indicating a shift to profitability, along with an adjusted net profit increase of 16.8% to RMB 17.6 million. The registered user base expanded by 15.8% to 52.8 million, supported by 11.9 million active monthly users, reflecting a remarkable 34.4% year-on-year growth.
User Engagement and Operational Excellence
With a growing body of 229,000 registered doctors and a pay-back repurchase rate of 85.4%, Fangzhou continues to enhance its service model. The product catalog has expanded to 216,000 SKUs, thanks to established relationships with over 1,650 suppliers and 980 pharmaceutical firms.
Innovations in Chronic Disease Management
At its 10th Healthcare Ecosystem Conference, Fangzhou showcased its proprietary “XingShi” Large Language Model (XS LLM). This advanced AI system is designed to tackle inefficiencies in chronic disease management, enhancing service delivery and personalizing patient care.
Technological Advancements through AI
XS LLM employs various technologies, including image and speech recognition, natural language processing, and extensive medical knowledge, to deliver high performance in medical AI applications. It powers several intelligent agents such as AI Knowledge Agent and AI Doctor Assistant, forming an integrated service network aimed at comprehensive chronic disease management.
Strategic Partnerships to Enhance Digital Health
During the conference, Fangzhou announced its strategic alliances with Innovent Biologics and Zhejiang Otsuka Pharmaceutical. These collaborations aim to advance digital health solutions, capitalizing on Fangzhou’s expertise in AI and platform operations to develop new health management models that align with the “Healthy China 2030” initiative.
About Fangzhou Inc.
Fangzhou Inc. (06086.HK) is recognized as a leading online platform offering chronic disease management solutions in China, with a user base of 52.8 million and 229,000 physicians. The company is dedicated to providing tailored healthcare and precision medicine through AI technologies. For more information about Fangzhou, visit the official site.
Media Contact
For further inquiries, contact:
Xingwei Zhao
Associate Director of Public Relations
Email: pr@jianke.com
Frequently Asked Questions
What award did Fangzhou receive recently?
Fangzhou was recognized as the “Outstanding Growth Story in Hong Kong Stocks” at the China Capital Market Development Forum.
What are Fangzhou's recent financial highlights?
Fangzhou reported a revenue of RMB 1.5 billion, net profit of RMB 12.5 million, and an impressive adjusted net profit increase of 16.8%.
How many registered users does Fangzhou have?
As of June 30, 2025, Fangzhou has 52.8 million registered users on its platform.
What technological innovations are being developed by Fangzhou?
Fangzhou has launched the XS LLM, an AI system geared towards improving chronic disease management through enhanced service efficiency and personalization.
What strategic partnerships has Fangzhou established?
Fangzhou formed strategic alliances with Innovent Biologics and Zhejiang Otsuka Pharmaceutical to enhance digital health management and collaboration.
